A5069988175- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Intraperitoneal and Appendiceal Malignancies
- Hippo pathway signaling and YAP/TAZ
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Head and Neck Cancer Studies
- Tumors and Oncological Cases
- Cancer Cells and Metastasis
- Pancreatitis Pathology and Treatment
- Ovarian cancer diagnosis and treatment
- Esophageal and GI Pathology
- Gallbladder and Bile Duct Disorders
- Cancer Genomics and Diagnostics
- interferon and immune responses
- MicroRNA in disease regulation
- Helicobacter pylori-related gastroenterology studies
The University of Texas MD Anderson Cancer Center
2016-2025
Queen Alexandra Hospital
2024
Brigham and Women's Hospital
2015
Baylor College of Medicine
2015
The University of Texas Southwestern Medical Center
2015
Loyola University Medical Center
2015
Universidad de Murcia
2015
Santa Lucía University General Hospital
2015
Hospital Universitario Virgen de la Arrixaca
2015
ARUP Laboratories (United States)
2015
Peritoneal carcinomatosis (PC) occurs frequently in patients with gastric adenocarcinoma (GAC) and confers a poor prognosis. Multiplex profiling of primary GACs has been insightful but the underpinnings PC's development/progression remain largely unknown. We characterised exome/transcriptome/immune landscapes PC cells from GAC aiming to identify novel therapeutic targets.We performed whole-exome sequencing (WES) whole transcriptome (RNA-seq) on 44 specimens (43 PC) including an integrative...
Peritoneal carcinomatosis (PC; malignant ascites or implants) occurs in approximately 45% of advanced gastric adenocarcinoma (GAC) patients and associated with a poor survival. The molecular events leading to PC are unknown. yes-associated protein 1 (YAP1) oncogene has emerged many tumour types, but its clinical significance is unclear. Here, we investigated the role YAP1 potential as therapeutic target.Patient-derived cells, patient-derived xenograft (PDX) orthotopic (PDO) models were used...
Abstract BACKGROUND: Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC). However, analysis of prognostic factors limited patients with PDAC treated neoadjuvant and pancreaticoduodenectomy (PD). METHODS: The study population was comprised 240 consecutive who received PD compared 60 had no therapy between 1999 2007. Clinicopathologic features were correlated disease‐free survival (DFS) overall (OS). RESULTS: Among the...
Objective Gastro-oesophageal cancers (GEC) are resistant to therapy and lead poor prognosis. The cancer stem cells (CSCs) antiapoptotic pathways often confer resistance. We sought elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC vitro, vivo clinical trial. Methods Extensive preclinical studies vitro were carried out establish mechanism on targeting CSCs proteins. A pilot trial patients with was completed AT-101 added standard chemoradiation. Results Overexpression MCL-1...
Abstract Purpose: Prognostic uncertainty is a major challenge for cancer of unknown primary (CUP). Current models limit meaningful patient-provider dialogue. We aimed to establish nomogram predicting overall survival (OS) in CUP based on robust clinicopathologic prognostic factors. Experimental Design: evaluated 521 patients with at MD Anderson Cancer Center (MDACC; Houston, TX; 2012–2016). Baseline variables were analyzed using Cox regression and developed significant predictors. Predictive...
Abstract BACKGROUND: Studies have shown that superior mesenteric vein (SMV)/portal (PV) resection with pancreaticoduodenectomy (PD) is safe and feasible for patient pancreatic adenocarcinoma (PAC). However, the prognostic significance of tumor involvement resected in patients who received neoadjuvant therapy unclear. METHODS: The authors evaluated 225 consecutive stage II PAC PD or without SMV/PV resection. was entirely submitted histologic assessment reviewed all cases. Tumor correlated...
Negative-margin resection is crucial to favorable prognosis in patients with pancreatic ductal adenocarcinoma. However, the definition of a negative superior mesenteric artery margin (SMAM) varies. The College American Pathologists defines positive SMAM as presence tumor cells at margin, whereas European protocol based on 1 mm clearance. In this study, we examined prognostic significance distance 411 consecutive adenocarcinoma who completed neoadjuvant therapy and pancreaticoduodenectomy....
<b><i>Background:</i></b> Patients with localized gastric adenocarcinoma (LGAC), who get pre-operative therapy, have heterogeneous/unpredictable outcomes. Predictive clinical variables/biomarkers are not established. <b><i>Methods:</i></b> We analyzed 107 LGAC patients had chemoradiation and surgery. LGACs were grouped for (1) presence/absence of signet ring cell histology (SRC) (2) histologic grade: G2 or G3. %SRC was assessed (0, 1-10, 11-49,...
Aims This study is to examine the significance of number and ratio positive nodes in post‐neoadjuvant therapy pancreaticoduodenectomy ( PD ) for pancreatic ductal adenocarcinoma PDAC ). Methods results Our population consisted 398 consecutive patients, who completed neoadjuvant between 1999 2012. Lymph node status was classified as ypN0 (node‐negative), ypN1 (1–2 nodes) ypN2 (≥3 correlated with disease‐free survival DFS overall OS The ypN0, present 183 (46.0%), 117 (29.4%) 98 (24.6%)...
Intrabiliary growth by metastatic colorectal carcinoma (CRC) is an unusual finding that can clinically mimic cholangiocarcinoma. We evaluated prevalence of intrabiliary retrospective review 1596 diagnostic reports and prospective evaluation 223 hepatectomies. Positive cases were scored for extent (major vs. minor duct involvement), architectural pattern (colonization biliary epithelium and/or tumor plugs), secondary sclerosing cholangitis in non-neoplastic parenchyma. By review, we...
Context.—The PI3K-AKT-mTOR (phosphatidylinositol 3-kinase–AKT–mammalian target of rapamycin) pathway plays a crucial role in subset advanced pancreatic neuroendocrine tumors (PanNETs). In breast and endometrial carcinoma, activation this inhibits progesterone receptor (PR) expression. Objective.—To determine whether combined low expression PR phosphatase tensin homologue (PTEN), negative regulator the pathway, is prognostic factor. Design.—A total 160 resected PanNETs (89 grade 71...